Literature DB >> 18407464

Betagamma subunits of G(i/o) suppress EGF-induced ERK5 phosphorylation, whereas ERK1/2 phosphorylation is enhanced.

Yutaro Obara1, Yumiko Okano, Sachiko Ono, Arata Yamauchi, Tomohiro Hoshino, Hitoshi Kurose, Norimichi Nakahata.   

Abstract

Extracellular signal-regulated kinases (ERKs) play important physiological roles in proliferation, differentiation and gene expression. ERK5 is twice the size of ERK1/2, the amino-terminal half contains the kinase domain that shares the homology with ERK1/2 and TEY activation motif, whereas the carboxy-terminal half is unique. In this study, we examined the cross-talk mechanism between G-protein-coupled receptors (GPCRs) and receptor tyrosine kinases, focusing on ERK1/2 and 5. The pretreatment of rat pheochromocytoma cells (PC12) with pertussis toxin (PTX) specifically enhanced epidermal growth factor (EGF)-induced ERK5 phosphorylation. In addition, lysophosphatidic acid (LPA) attenuated the EGF-induced ERK5 phosphorylation in LPA(1) receptor- and G(i/o)-dependent manners. On the other hand, LPA alone activated ERK1/2 via Gbetagamma subunits and Ras and potentiated EGF-induced ERK1/2 phosphorylation at late time points. These results suggest G(i/o) negatively regulates ERK5, while it positively regulates ERK1/2. LPA did not affect cAMP levels after EGF treatment, and the reagents promoting cAMP production such as forskolin and cholera toxin also attenuated the EGF-induced ERK5 phosphorylation, indicating that the inhibitory effect of LPA on ERK5 inhibition via G(i/o) is not due to inhibition of adenylyl cyclase by Galpha(i/o). However, the inhibitory effect of LPA on ERK5 was abolished in PC12 cells stably overexpressing C-terminus of GPCR kinase2 (GRK2), and overexpression of Gbeta(1) and gamma(2) subunits also suppressed ERK5 phosphorylation by EGF. In response to LPA, Gbetagamma subunits interacted with EGF receptor in a time-dependent manner. These results strongly suggest that LPA negatively regulates the EGF-induced ERK5 phosphorylation through Gbetagamma subunits.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18407464     DOI: 10.1016/j.cellsig.2008.02.016

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  7 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

Review 2.  Structure, biological functions and applications of the AB5 toxins.

Authors:  Travis Beddoe; Adrienne W Paton; Jérôme Le Nours; Jamie Rossjohn; James C Paton
Journal:  Trends Biochem Sci       Date:  2010-03-02       Impact factor: 13.807

3.  Somatostatin activates Ras and ERK1/2 via a G protein βγ-subunit-initiated pathway in thyroid cells.

Authors:  Francisco J Rodríguez-Álvarez; Eva Jiménez-Mora; María Caballero; Beatriz Gallego; Antonio Chiloeches; Ma José Toro
Journal:  Mol Cell Biochem       Date:  2015-10-16       Impact factor: 3.396

4.  Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.

Authors:  Robert B Laprairie; Amina M Bagher; Melanie E M Kelly; Denis J Dupré; Eileen M Denovan-Wright
Journal:  J Biol Chem       Date:  2014-07-18       Impact factor: 5.157

5.  ERK5 activity is required for nerve growth factor-induced neurite outgrowth and stabilization of tyrosine hydroxylase in PC12 cells.

Authors:  Yutaro Obara; Arata Yamauchi; Shin Takehara; Wataru Nemoto; Maho Takahashi; Philip J S Stork; Norimichi Nakahata
Journal:  J Biol Chem       Date:  2009-07-06       Impact factor: 5.157

6.  Phosphorylation of ERK5 on Thr732 is associated with ERK5 nuclear localization and ERK5-dependent transcription.

Authors:  Takuto Honda; Yutaro Obara; Arata Yamauchi; Anthony D Couvillon; Justin J Mason; Kuniaki Ishii; Norimichi Nakahata
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

Review 7.  Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.